Author

M. J. Lallena

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

C. Marugan· 2 shared A. Alonso de la Vega· 1 shared A. de Dios· 1 shared A. Monfort-Vengut· 1 shared A. Teijo· 1 shared B. Ortigosa· 1 shared C. Baquero· 1 shared C. Bertinetti· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Marugan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TPX2 expression promotes sensitivity to dasatinib in breast cancer by activating the YAP transcriptional signaling.

C. Marugan, B. Ortigosa, N. Sanz-Gomez, A. Monfort-Vengut, C. Bertinetti, A. Teijo, M. Gonzalez, A. Alonso de la Vega, M. J. Lallena, G. Moreno-Bueno, G. de Carcer

The paper identifies TPX2 as a gene that increases breast cancer sensitivity to dasatinib by activating the YAP pathway, and shows TPX2 and YAP are biomarkers for poor prognosis and potential dasatinib therapy.

bioRxiv · Sep 4, 2023Cancer Biology

Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclib.

R. Torres-Guzman, M. P. Ganado, C. Mur, C. Marugan, C. Baquero, Y. Yang, Y. Zeng, H. Bian, J. Du, A. de Dios, O. Puig, M. J. Lallena

This study shows abemaciclib, a CDK4/6 inhibitor, effectively inhibits cell proliferation and induces apoptosis with continuous treatment, outperforming other CDK4/6 inhibitors in breast cancer cell lines.

bioRxiv · Nov 15, 2021 · PreprintCell Biology